Compare FLS & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLS | CORT |
|---|---|---|
| Founded | 1790 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 7.6B |
| IPO Year | N/A | N/A |
| Metric | FLS | CORT |
|---|---|---|
| Price | $69.73 | $82.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | $76.40 | ★ $130.20 |
| AVG Volume (30 Days) | ★ 1.4M | 852.0K |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | ★ 69.42 | N/A |
| EPS | ★ 3.44 | 0.87 |
| Revenue | ★ $4,687,417,000.00 | $741,172,000.00 |
| Revenue This Year | $5.80 | $23.79 |
| Revenue Next Year | $4.04 | $40.97 |
| P/E Ratio | ★ $20.12 | $94.20 |
| Revenue Growth | 3.19 | ★ 17.92 |
| 52 Week Low | $37.34 | $49.00 |
| 52 Week High | $74.63 | $117.33 |
| Indicator | FLS | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 51.07 |
| Support Level | $68.91 | $78.07 |
| Resistance Level | $74.63 | $89.00 |
| Average True Range (ATR) | 1.89 | 3.47 |
| MACD | -0.65 | -0.31 |
| Stochastic Oscillator | 14.51 | 37.54 |
Flowserve Corp is a manufacturer and aftermarket service provider of comprehensive flow control systems. It develops precision-engineered flow control equipment to monitor movement and protect customers' materials and processes. It offers an extensive range of pumps, valves, seals, and services for several industries, including oil and gas, chemical, power generation, and water management. It has three business segments: FPD for custom engineered pumps, pre-configured industrial pumps, pump systems, mechanical seals, auxiliary systems and replacement parts and related services; and FCD for engineered-to-order and configured-to-order isolation values, control valves, valve automation products and related equipment and Eliminations and All Other.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.